Silab Group Subsidiary Siltiss Signs Deal with Inserm

Author Image

By: TOM BRANNA

Editor

FRANCE: SILTISS, the new subsidiary of the Silab Group founded in January 2016, has acquired exclusive rights to use a tissue engineering technology developed by Inserm. The exclusive accord was signed in April by Pascale Augé, chairman of the board of directors, Inserm Transfert, and Jean Paufique, chairman and founder of Siltiss. Siltiss develops, produces and markets natural-origin biomaterials that promote or induce the tissue regeneration process. The initial applications relate to bone ...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters